Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

ABSTRACT:

Background

The purpose of this study was to identify any differences in key biomarkers associated with estrogen action between biopsies taken at diagnosis and at recurrence or progression during treatment with an aromatase inhibitor (AI).

Patients and methods

Patients were retrospectively identified from a clinical database as having relapsed or progressed during AI treatment. Immunohistochemistry was carried out against estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), insulin-like growth factor type-1 receptor (IGF1R), insulin receptor substrate-1 (IRS-1), stathmin, phosphatase and tensin homolog and Ki67.

Results

Fifty-five pairs of samples were identified with ER- and/or PgR-positive diseases. Four (7%) patients

SUBMITTER: Arnedos M 

PROVIDER: S-EPMC3933249 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature